# SAFETY DATA SHEET



1. Identification

**Product identifier PAXIL ORAL SUSPENSION** 

Other means of identification

Not available.

SEROXAT LIQUID \* SEROXAT SUSPENSION \* DEROXAT SUSPENSION \* FORMULA CODE Synonym(s)

B046 \* PAROXETINE HYDROCHLORIDE, FORMULATED PRODUCT

Recommended use Medicinal Product

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

**Recommended restrictions** No other uses are advised. Manufacturer/Importer/Supplier/Distributor information

Manufacturer

GlaxoSmithKline US 5 Moore Drive

Research Triangle Park, NC 27709 USA

US General Information (normal business hours): +1-888-825-5249

Email Address: msds@gsk.com Website: www.gsk.com **EMERGENCY PHONE NUMBERS -**TRANSPORT EMERGENCIES::

+1 703 527 3887 US / International toll call

available 24 hrs/7 days; multi-language response

## 2. Hazard(s) identification

#### Classified hazards

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

#### I abel elements

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

#### Hazard(s) not otherwise classified (HNOC)

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

## 3. Composition/information on ingredients

#### **Mixtures**

**Hazardous components** 

**HEMIHYDRATE** 

**Chemical name** Common name and synonyms % **CAS** number PAROXETINE HYDROCHLORIDE (-)-TRANS-4-(4-FLUOROPHENYL)-3-(3,4-ME 110429-35-1 < 1

HYDROCHLORIDE HEMIHYDRATE

BRL-29060A

3119 Version #: 13 Revision date: 11-25-2013 Issue date: 11-25-2013

Material name: PAXIL ORAL SUSPENSION

Hazardous components Chemical name	Common name and synonyms	CAS number	%
TITANIUM DIOXIDE	ANATASE BROOKITE RUTILE TITANIUM OXIDE TITANIUM DIOXIDE (TiO2) C.I. PIGMENT WHITE 6 C.I. 77891 TITANIUM(IV) OXIDE TITANIUM(4+) OXIDE TITANIUM PEROXIDE (TiO2) TITANIA (TiO2) PIGMENT WHITE 6 TITANIA KRONOS TITANIC OXIDE O2Ti OHS23510 RTECS XR2275000 DIOXIDO DE TITANIO TITAANOKSIID	13463-67-7	<1
CITRIC ACID ANHYDROUS	BETA-HYDROXYTRICARBALLYLIC ACID ANHYDROUS CITRIC ACID 2-HYDROXY-1,2,3-PROPANETRICARBOXY ACID CITIRIC ACID	77-92-9	< 0.3
Other components below reportable levels			>98.0

<sup>\*</sup>Designates that a specific chemical identity and/or percentage of composition has been withheld as a trade secret.

## 4. First-aid measures

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard. Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse. Get medical attention if symptoms occur.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large amount does occur, call a poison control center immediately.

Most important The following adverse effects have been noted with therapeutic use of this material: nausea; diarrhoea; constipation; dry mouth; drowsiness; dizziness; weakness; insomnia; sexual symptoms/effects, acute and dysfunction; tremor; palpitations. delayed

Indication of immediate No specific antidotes are recommended. Treat according to locally accepted protocols. For medical attention and special additional guidance, refer to the current prescribing information or to the local poison control treatment needed information centre.

Pre-placement and periodic health surveillance is not usually indicated. The final determination of **General information** the need for health surveillance should be determined by local risk assessment.

# 5. Fire-fighting measures

Specific hazards arising from

Suitable extinguishing media Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Unsuitable extinguishing None known.

media

the chemical

Special protective equipment Self-contained breathing apparatus and full protective clothing must be worn in case of fire. and precautions for firefighters

During fire, gases hazardous to health may be formed.

In the event of fire, cool tanks with water spray. equipment/instructions

Specific methods Move containers from fire area if you can do so without risk.

# 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate personal protective equipment. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8 of the MSDS.

3119 Version #: 13 Revision date: 11-25-2013 Issue date: 11-25-2013

#### Methods and materials for containment and cleaning up

Large Spills: Stop the flow of material, if this is without risk. Dike the spilled material, where this is possible. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills in original containers for re-use. For waste disposal, see section 13 of the MSDS.

**Environmental precautions** 

Avoid release to the environment. Contact local authorities in case of spillage to drain/aquatic environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground.

#### 7. Handling and storage

Precautions for safe handling

Avoid prolonged exposure. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. Avoid release to the environment. Do not empty into drains.

Conditions for safe storage, including any incompatibilities

Store in original tightly closed container. Store in a cool, dry place out of direct sunlight. Store away from incompatible materials (see Section 10 of the MSDS).

# 8. Exposure controls/personal protection

#### Occupational exposure limits

GSK

GON			
Components	Туре	Value	Note
CITRIC ACID ANHYDROUS (CAS 77-92-9)	8 HR TWA	5000 mcg/m3	
,	OHC	1	
PAROXETINE HYDROCHLORIDE HEMIHYDRATE (CAS 110429-35-1)	8 HR TWA	40 mcg/m3	
,	OHC	3	REPRODUCTIVE HAZARD
US. OSHA Table Z-1 Limits for Air (	Contaminants (29 CFR 1910.1000)		
Components	Туре	Value	Form
TITANIUM DIOXIDE (CAS 13463-67-7)	PEL	15 mg/m3	Total dust.
<b>US. ACGIH Threshold Limit Values</b>			
Components	Туре	Value	
TITANIUM DIOXIDE (CAS 13463-67-7)	TWA	10 mg/m3	

#### Biological limit values

No biological exposure limits noted for the ingredient(s).

Appropriate engineering

controls

Use process enclosures, local exhaust ventilation, or other engineering controls to control airborne levels below recommended exposure limits. An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment.

# Individual protection measures, such as personal protective equipment

Eye/face protection Chemical goggles are recommended. Eye wash fountains are required.

Hand protection The choice of an appropriate glove does not only depend on its material but also on other quality

features and is different from one producer to the other. Glove selection must take into account

any solvents and other hazards present.

Wear appropriate chemical resistant clothing. Other

Respiratory protection

In case of insufficient ventilation, wear suitable respiratory equipment.

Thermal hazards

Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

An occupational/industrial hygiene monitoring method has been developed for this material. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. New or expectant mothers might be at greater risk from overexposure. Risk assessments must take this into consideration. Female employees anticipating pregnancy or with a confirmed pregnancy must be encouraged to notify an occupational health professional or their line manager. This will act as the trigger for individual re-assessment of the employee's work practices.

Material name: PAXIL ORAL SUSPENSION

# 9. Physical and chemical properties

**Appearance** 

Physical state Liquid. **Form** Suspension. Color Not available. Odor Not available. Not available. Odor threshold рΗ Not available. Not available. Melting point/freezing point Initial boiling point and boiling Not available.

range

Not available. Flash point Not available. **Evaporation rate** Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

Flammability limit - upper

Not available.

(%)

Not available. Explosive limit - lower (%) Not available. Explosive limit - upper (%)

Vapor pressure Not available. Not available. Vapor density Relative density Not available. Solubility(ies) Not available. Not available. **Partition coefficient** 

(n-octanol/water)

**Auto-ignition temperature** Not available. Not available. **Decomposition temperature** Not available. **Viscosity** 

## 10. Stability and reactivity

Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

**Chemical stability** Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials. Incompatible materials Strong oxidizing agents. Fluorine.

Hazardous decomposition

products

Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

# 11. Toxicological information

## Information on likely routes of exposure

Ingestion May be harmful if swallowed.

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard.

Skin contact May be irritating to the skin.

Eye contact Irritation can occur following direct contact with this material. Risk of serious damage to eyes. Symptoms related to the The following adverse effects have been noted with therapeutic use of this material: nausea; diarrhoea; constipation; dry mouth; drowsiness; dizziness; weakness; insomnia; sexual physical, chemical and

toxicological characteristics

May be harmful if swallowed. May irritate eyes and skin. **Acute toxicity** 

dysfunction; tremor; palpitations.

Material name: PAXIL ORAL SUSPENSION

Information on toxicological effects

4 / 10

**Test Results** Components **Species** 

CITRIC ACID ANHYDROUS (CAS 77-92-9)

Acute

Oral

LD50 Rat 3000 mg/kg

PAROXETINE HYDROCHLORIDE HEMIHYDRATE (CAS 110429-35-1)

Acute

Oral LD50

Rat 374 mg/kg

Chronic

Oral

TD

**NOAEL** Monkey 3.5 mg/kg/day, 52 weeks

> Rat 5 mg/kg/day, 52 weeks Monkey 6 mg/kg/day, 52 weeks

Rat 25 mg/kg/day, 52 weeks

TITANIUM DIOXIDE (CAS 13463-67-7)

**Acute** 

Inhalation

LC50 Rat 6820 mcg/m3

Oral

LD50 Rat > 24 g/kg

Chronic

Inhalation

LOEC Rat 8.6 mg/m3, 1 years, TiO2 accumulated in

interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.

NOAEC 250 mg/m3, 2 years, Highest dose Rat

5 mg/m3, 24 months

**Subacute** 

Inhalation

LOEL Rat 0.1 - 35 mg/m3, 4 weeks, Mild macrophage

hyperplasia, no change in

bronchio-alveolar lavage fluid.

NOAEC Guinea pig 26 mg/m3, 3 weeks, No evidence of

significant inflammation in respiratory tract.

Oral

NOAEL 100000 ppm, 14 Day, Dietary study, Rat

highest dose tested.

**Subchronic** 

Inhalation

LOEC Rat

3.2 - 20 mg/m3, 8 min, Accumulation of TiO2 in macrophages and evidence of

pulmonary inflammation.

Skin corrosion/irritation Prolonged skin contact may cause temporary irritation.

**Irritation Corrosion - Skin** 

TITANIUM DIOXIDE Acute dermal irritation; OECD 404, Literature data

Result: Non-irritant Species: Rabbit

PAROXETINE HYDROCHLORIDE HEMIHYDRATE Acute dermal irritation; OECD 404, Primary Irritation Index: 0

Result: Non-irritating to intact skin

Species: Rabbit

Acute dermal irritation; OECD 404, Primary Irritation Index: 3

Result: Irritating to damaged skin.

Species: Rabbit Literature data

Result: Non-irritant Species: Guinea pig

Material name: PAXIL ORAL SUSPENSION

TITANIUM DIOXIDE

<sup>\*</sup> Estimates for product may be based on additional component data not shown.

Irritation Corrosion - Skin

TITANIUM DIOXIDE Literature data

Result: Non-irritant Species: Human

Serious eye damage/eye irritation

TITANIUM DIOXIDE

Eye

PAROXETINE HYDROCHLORIDE HEMIHYDRATE OECD 405, Kay and Calndra - Grade 8.

Result: Very severe irritant

Species: Rabbit

TITANIUM DIOXIDE OECD 405, Literature data

Result: Mild irritant Species: Rabbit

Respiratory sensitization Not available.

**Skin sensitization** This product is not expected to cause skin sensitization.

Sensitization

TITANIUM DIOXIDE 5 % Optimisation Test, Literature data - Vehicle: petrolatum

Result: Negative Species: Guinea pig

Test Duration: 48 hour exposure

PAROXETINE HYDROCHLORIDE HEMIHYDRATE OECD 406, 0 % Response rate.

Result: Negative Species: Guinea pig

TITANIUM DIOXIDE Patch test, Literature data

Result: Negative Species: Human

Germ cell mutagenicity

No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

PAROXETINE HYDROCHLORIDE HEMIHYDRATE Ames - Screen

Result: Negative Ames, Literature data Result: Negative

PAROXETINE HYDROCHLORIDE HEMIHYDRATE Chromosomal Aberration Assay In Vitro

Result: Negative

GreenScreen mammalian cell mutation assay

Result: Negative

L5178Y mouse lymphoma thymidine kinase locus assay, GLP

Result: Negative

TITANIUM DIOXIDE Micronucleus Assay in vitro, CHO cells, Literature data

Result: Negative

Micronucleus Assay in vitro, cultured human peripheral

lymphocytes, Literature data

Result: Positive

PAROXETINE HYDROCHLORIDE HEMIHYDRATE Micronucleus Assay, GLP

Result: Negative Species: Mouse

Mutation in Drosophila melanogaster

Result: Negative

Sister Chromatid Exchange

Result: Negative

TITANIUM DIOXIDE Syrian Hamster Embryo (SHE) cell transformation assay

Result: Negative

PAROXETINE HYDROCHLORIDE HEMIHYDRATE Unscheduled DNA Synthesis, in vivo - in vitro

Result: Negative Species: Rat

TITANIUM DIOXIDE WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Result: Positive

Carcinogenicity Titanium dioxide is listed as a carcinogen by external agencies. Carcinogenic activity was seen in

inhalation studies using laboratory animals. High concentrations or doses administered over an

extended period of time were required to produce adverse effects.

0.5 mg/m3, Literature data

Result: Negative Species: Rat

Test Duration: 24 months

0.72 - 14.8 mg/m3, Literature data

Result: Negative Species: Mouse

Material name: PAXIL ORAL SUSPENSION

TITANIUM DIOXIDE

Carcinogenicity

TITANIUM DIOXIDE 10 - 250 mg/m3, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar

adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months 25000 - 50000 ppm, Dietary study

Result: Negative Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: Negative Species: Rat

7.2 - 14.8 mg/m3, Literature data

Result: Lung tumour

Species: Rat

Test Duration: 24 months

PAROXETINE HYDROCHLORIDE HEMIHYDRATE Result: Negative

Species: Mouse

Test Duration: 18 months

Result: Negative Species: Rat

Test Duration: 2 years

IARC Monographs. Overall Evaluation of Carcinogenicity

TITANIUM DIOXIDE (CAS 13463-67-7)

2B Possibly carcinogenic to humans.

Reproductive toxicity Epidemiology studies have identified the ingredient paroxetine hydrochloride hemihydrate as a

possible cause of developmental toxicity in humans.

PAROXETINE HYDROCHLORIDE HEMIHYDRATE 13 mg/kg/day Fertility, Female

Result: Maternal toxicity; adverse effects on offspring.

Species: Rat

13 mg/kg/day Fertility, Male

Result: Parental toxicity, no adverse effects on fertility.

Species: Rat

3 mg/kg/day Embryo-foetal development

Result: Maternal NOAEL

Species: Rabbit

4.3 mg/kg/day Fertility, Female

Result: NOAEL Species: Rat

5 mg/kg/day Embryo-foetal development

Result: NOAEL Species: Rat

6 mg/kg/day Embryofetal Development Result: Maternal toxicity; Foetal NOAEL

Species: Rabbit

>= 50 mg/kg/day Embryo-foetal development Result: Maternal toxicity; adverse foetal effects

Species: Rat

Embryo-foetal development, Possible association with

clinical use reported in epidemiology studies.

Species: Human

Organ: Cardiovascular malformations

Fertility, Male, Possible association with clinical use reported

in epidemiology studies.

Result: Reversible effects on sperm quality.

Species: Human

**Specific target organ toxicity -** Central nervous system. **single exposure** 

PAROXETINE HYDROCHLORIDE HEMIHYDRATE

Organ: Central Nervous System.

**Specific target organ toxicity -** May cause damage to organs through prolonged or repeated exposure.

repeated exposure

PAROXETINE HYDROCHLORIDE HEMIHYDRATE Epidemiology

Organ: Bone; Testes (reversible).

**Aspiration hazard** Not likely, due to the form of the product.

**Chronic effects** Prolonged exposure may cause chronic effects.

**Further information** Caution - Pharmaceutical agent.

Material name: PAXIL ORAL SUSPENSION
3119 Version #: 13 Revision date: 11-25-2013 Issue date: 11-25-2013

# 12. Ecological information

#### **Ecotoxicity**

No information is available about the potential of this product to produce adverse environmental effects. Contains a substance which causes risk of hazardous effects to the environment. The product contains a substance which may cause long-term adverse effects in the environment.

Components		Species	Test Results
CITRIC ACID ANHYDRO	US (CAS 77-92-	-9)	
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	120 mg/l, 72 hours, Static test
Fish	EC50	Bluegill sunfish (Adult Lepomis macrochirus)	1516 mg/l, 96 hours, Static test
		Golden ide/orfe (Adult Leuciscus idus)	440 - 760 mg/l, 96 hours, Static test
Microtox	EC50	Microtox	14 mg/l, 15 minutes
PAROXETINE HYDROCI	HLORIDE HEMI	HYDRATE (CAS 110429-35-1)	
Aquatic			
Acute			
Activated Sludge Respiration	IC50	Residential sludge	25 mg/L, 3 hours
Crustacea	EC50	Water flea (Daphnia magna)	2.5 mg/L, 48 hours, Static test, OECD 202
	NOEC	Water flea (Daphnia magna)	0.49 mg/L, 48 hours
Fish	EC50	Bluegill sunfish (Adult Lepomis macrochirus)	1.6 mg/L, 96 hours, Static test, OECD 203
	NOEC	Bluegill sunfish (Adult Lepomis macrochirus)	0.18 mg/L, 96 hours, Static test
Microtox	EC50	Microtox	8.2 mg/L, 15 minutes
Chronic			
Crustacea	LOEC	Water flea (Ceriodaphnia dubia)	0.5 mg/l, 7 days, Static renewal test, EPA 2002
	NOEC	Water flea (Ceriodaphnia dubia)	0.25 mg/L, 7 days
TITANIUM DIOXIDE (CA	S 13463-67-7)		
Aquatic	•		
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	> 1000 mg/l, 48 hours, Static test

<sup>\*</sup> Estimates for product may be based on additional component data not shown.

# Persistence and degradability

# **Photolysis**

Half-life (Photolysis-aqueous)

PAROXETINE HYDROCHLORIDE HEMIHYDRATE 2.4 Hours Measured, Deionized Water

UV/visible spectrum wavelength

PAROXETINE HYDROCHLORIDE HEMIHYDRATE 292 nm, pH 5-9

**Hydrolysis** 

Half-life (Hydrolysis-neutral)

PAROXETINE HYDROCHLORIDE HEMIHYDRATE > 1 Years Measured, Deionized Water

**Bioaccumulative potential** 

Partition coefficient n-octanol / water (log Kow)

PAROXETINE HYDROCHLORIDE HEMIHYDRATE 1.3

Mobility in soil

Adsorption

Sludge/biomass distribution coefficient - log Kd

PAROXETINE HYDROCHLORIDE HEMIHYDRATE 2.94 Measured

Soil/sediment sorption - log Koc

PAROXETINE HYDROCHLORIDE HEMIHYDRATE 0.8 Estimated

Mobility in general

Volatility

Henry's law

CITRIC ACID ANHYDROUS < 0 atm m^3/mol Calculated, 25 °C

Material name: PAXIL ORAL SUSPENSION

Volatility

Henry's law

PAROXETINE HYDROCHLORIDE HEMIHYDRATE 0 atm m3/mol Calculated

Other adverse effects Not available.

# 13. Disposal considerations

**Disposal instructions**Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not allow

this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches

with chemical or used container. Dispose of contents/container in accordance with

local/regional/national/international regulations.

Local disposal regulations

Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging

Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

# 14. Transport information

DOT

Not regulated as a dangerous good.

IATA

Not regulated as a dangerous good.

**IMDG** 

Not regulated as a dangerous good.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

environment. These materials may not be transported in bulk.

15. Regulatory information

**US federal regulations** 

This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication

Standard, 29 CFR 1910.1200.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

US. OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

SARA 304 Emergency release notification

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - Yes

Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

No

SARA 311/312 Hazardous

chemical

No

NFPA ratings

Health: 1

Flammability: 1 Instability: 0

HMIS® ratings

Health: 1\* Flammability: 1 Physical hazard: 0

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Material name: PAXIL ORAL SUSPENSION

3119 Version #: 13 Revision date: 11-25-2013 Issue date: 11-25-2013 9 / 10

# Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

(SDWA)

Not regulated.

Food and Drug

Administration (FDA)

Not regulated.

#### **US** state regulations

#### US. Massachusetts RTK - Substance List

TITANIUM DIOXIDE (CAS 13463-67-7)

#### US. New Jersey Worker and Community Right-to-Know Act

Not regulated.

## US. Pennsylvania RTK - Hazardous Substances

TITANIUM DIOXIDE (CAS 13463-67-7)

#### **US. Rhode Island RTK**

Not regulated.

#### **US. California Proposition 65**

WARNING: This product contains a chemical known to the State of California to cause cancer.

#### US - California Proposition 65 - CRT: Listed date/Carcinogenic substance

Inventory name

TITANIUM DIOXIDE (CAS 13463-67-7) Listed: September 2, 2011

#### **International Inventories**

Country(s) or region

Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No

<sup>\*</sup>A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

Toxic Substances Control Act (TSCA) Inventory

# 16. Other information, including date of preparation or last revision

Issue date 11-25-2013 **Revision date** 11-25-2013

Version # 13

NFPA ratings

United States & Puerto Rico

**Further information** Not available. **HMIS®** ratings Health: 1\* Flammability: 1 Physical hazard: 0

Health: 1 Flammability: 1

Instability: 0

References **GSK Hazard Determination** Disclaimer

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Product and Company Identification: Physical States Revision Information

> Composition / Information on Ingredients: Ingredients Physical & Chemical Properties: Multiple Properties

Transport Information: Agency Name, Packaging Type, and Transport Mode Selection

Material name: PAXIL ORAL SUSPENSION

3119 Version #: 13 Revision date: 11-25-2013 Issue date: 11-25-2013

Nο

On inventory (yes/no)\*